Anthem Bioscienc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0CZ201020
  • NSEID: ANTHEM
  • BSEID: 544449
INR
810.50
26.1 (3.33%)
BSENSE

Jul 31, 02:32 PM

BSE+NSE Vol: 9.19 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Ipca Labs
Ajanta Pharma
Gland Pharma
Glenmark Pharma
Sai Life
Emcure Pharma
Wockhardt
Anthem Bioscienc
Alkem Lab
Abbott India
Glaxosmi. Pharma

Why is Anthem Biosciences Ltd ?

1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 19.93%
  • Healthy long term growth as Operating profit has grown by an annual rate 44.32%
  • The company is Net-Debt Free
  • PAT(Q) At Rs 119.94 cr has Fallen at -21.2% (vs previous 4Q average)
  • NET SALES(Q) Lowest at Rs 418.22 cr
  • PBDIT(Q) Lowest at Rs 150.57 cr.
2
With ROE of 20, it has a Very Expensive valuation with a 14.5 Price to Book Value
  • Over the past year, while the stock has generated a return of NA, its profits have risen by 36%
3
Reducing Promoter Confidence
  • Promoters have decreased their stake in the company by -3.26% over the previous quarter and currently hold 71.42% of the company
  • Promoters decreasing their stake may signify reduced confidence in the future of the business
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Anthem Bioscienc should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
29.80%
EBIT Growth (5y)
44.32%
EBIT to Interest (avg)
92.24
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.63
Tax Ratio
26.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.05%
ROCE (avg)
32.62%
ROE (avg)
19.93%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
74
Industry P/E
37
Price to Book Value
14.50
EV to EBIT
65.99
EV to EBITDA
54.53
EV to Capital Employed
20.06
EV to Sales
21.59
PEG Ratio
NA
Dividend Yield
0.26%
ROCE (Latest)
32.47%
ROE (Latest)
20.02%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bollinger Bands
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
PAT(Latest six months)

At Rs 309.03 cr has Grown at 41.49%

-14What is not working for the Company
PAT(Q)

At Rs 119.94 cr has Fallen at -21.2% (vs previous 4Q average

NET SALES(Q)

Lowest at Rs 418.22 cr

PBDIT(Q)

Lowest at Rs 150.57 cr.

PBT LESS OI(Q)

Lowest at Rs 119.69 cr.

Loading Valuation Snapshot...

Here's what is not working for Anthem Bioscienc

Net Sales - Quarterly
At Rs 418.22 cr has Fallen at -21.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 531.08 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 119.69 cr has Fallen at -30.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 173.21 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 119.94 cr has Fallen at -21.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 152.29 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Quarterly
Lowest at Rs 418.22 cr
in the last five quarters
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs 150.57 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 119.69 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)